Erosive Hand Osteoarthritis
Cross-source consensus on Erosive Hand Osteoarthritis from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Evidence quality
Other
Highlighted claims
- Hand osteoarthritis is common and disabling, with fewer effective treatment options than hip or knee osteoarthritis. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Erosive hand osteoarthritis is described as an inflammatory phenotype linked to pain and disease progression. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Existing disease-modifying and biologic treatments used in rheumatoid or psoriatic arthritis have had limited success in erosive hand osteoarthritis. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Older adults have high reported age-standardized prevalence of hand osteoarthritis in both women and men. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Denosumab trial results support the possibility that structural modification is achievable in erosive hand osteoarthritis. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial